Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
327.41
-5.44 (-1.63%)
Feb 25, 2026, 11:01 AM EST - Market open
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 27 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $472.78, which forecasts a 44.40% increase in the stock price over the next year. The lowest target is $351 and the highest is $583.
Price Target: $472.78 (+44.40%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 13 | 13 | 13 | 12 | 13 |
| Buy | 11 | 11 | 10 | 10 | 10 | 10 |
| Hold | 4 | 3 | 4 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 27 | 27 | 28 | 27 | 28 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $510 | Strong Buy | Reiterates | $510 | +55.77% | Feb 18, 2026 |
| Freedom Capital Markets | Freedom Capital Markets | Hold → Strong Buy Upgrades $470 → $410 | Hold → Strong Buy | Upgrades | $470 → $410 | +25.23% | Feb 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $415 → $429 | Strong Buy | Maintains | $415 → $429 | +31.03% | Feb 17, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $475 → $425 | Strong Buy | Maintains | $475 → $425 | +29.81% | Feb 13, 2026 |
| Needham | Needham | Strong Buy Maintains $529 → $510 | Strong Buy | Maintains | $529 → $510 | +55.77% | Feb 12, 2026 |
Financial Forecast
Revenue This Year
5.63B
from 3.71B
Increased by 51.70%
Revenue Next Year
7.32B
from 5.63B
Increased by 29.84%
EPS This Year
6.70
from 2.33
Increased by 187.51%
EPS Next Year
13.00
from 6.70
Increased by 94.00%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.4B | 8.6B | |||
| Avg | 5.6B | 7.3B | |||
| Low | 4.8B | 6.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 72.0% | 52.4% | |||
| Avg | 51.7% | 29.8% | |||
| Low | 28.0% | 7.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 9.82 | 20.43 | |||
| Avg | 6.70 | 13.00 | |||
| Low | 2.13 | 7.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 321.4% | 205.0% | |||
| Avg | 187.5% | 94.0% | |||
| Low | -8.7% | 17.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.